ADPKD的表观遗传调控、炎症和甲基化的分子机制
The Molecular Mechanisms of Epigenetic Regulation, Inflammation, and Methylation in ADPKD
DOI: 10.12677/ACM.2023.13112426, PDF,   
作者: 李林斌, 宋光鲁*:新疆医科大学第一附属医院泌尿外科,新疆 乌鲁木齐
关键词: ADPKD表观遗传学修饰炎症DNA甲基化ADPKD Epigenetics Modification Inflammation DNA Methylation
摘要: 常染色体显性多囊肾病(ADPKD)是一种由PKD1和PKD2基因突变引起的遗传性疾病,其特征是肾脏中多个囊肿的进行性生长,最终导致终末期肾病(ESKD),需要肾脏替代治疗。研究表明,疾病的进展是多种因素共同作用的结果。因此,了解分子机制将有助于制定ADPKD治疗的精确治疗策略。表观遗传调节、间质炎症和细胞调控死亡的作用最近成为ADPKD研究的热点。不同的表观遗传调节因子表达与囊肿进展有关的炎症标志物,在囊肿生长之前就可检测到。此外,在人类和PKD动物模型中,炎症细胞(如巨噬细胞和T细胞)的浸润与囊肿生长和肾功能恶化有关。然而,在ADPKD中,细胞死亡是否促进或延迟囊肿生长还没有达成共识。因此,有必要研究PKD基因突变、表观基因组、炎症和细胞死亡之间的交互关系,以理解为什么患者的遗传性PKD基因突变可能导致这些过程的失调,从而增加肾囊肿的进展。
Abstract: Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease caused by mutations in the PKD1 and PKD2 genes, characterized by the progressive growth of multiple cysts in the kidney, ultimately leading to end-stage kidney disease (ESKD) and requiring renal replacement therapy. Research has shown that the progression of diseases is the result of multiple factors working to-gether. Therefore, understanding the molecular mechanisms will help develop precise treatment strategies for ADPKD. The role of epigenetic regulation, interstitial inflammation, and cell death regulation has recently become a hot topic in ADPKD research. Inflammatory markers related to the expression of different epigenetic regulatory factors and cyst progression can be detected be-fore cyst growth. In addition, in human and PKD animal models, the infiltration of inflammatory cells (such as macrophages and T cells) is associated with cyst growth and deterioration of renal function. However, there is no consensus on whether cell death promotes or delays cyst growth in ADPKD. Therefore, it is necessary to study the interaction between PKD gene mutations, epige-nomes, inflammation, and cell death in order to understand why genetic PKD gene mutations in pa-tients may lead to dysregulation of these processes, thereby increasing the progression of renal cysts.
文章引用:李林斌, 宋光鲁. ADPKD的表观遗传调控、炎症和甲基化的分子机制[J]. 临床医学进展, 2023, 13(11): 17315-17321. https://doi.org/10.12677/ACM.2023.13112426

参考文献

[1] 姚安琪, 郑艳辉. 托伐普坦治疗肾脏疾病的应用[J]. 医学信息,2020, 33(24): 53-55, 62.
[2] Srut, M. (2021) Eco-toxicological Epigenetics in Invertebrates: Emerging Tool for the Evaluation of Present and Past Pollution Burden. Chemosphere, 282, Article ID: 131026. [Google Scholar] [CrossRef] [PubMed]
[3] Bowden, S.A., et al. (2021) Recent Discoveries in Epigenetic Modifications of Polycystic Kidney Disease. International Journal of Molec-ular Sciences, 22, Article 13327. [Google Scholar] [CrossRef] [PubMed]
[4] Safi, W., et al. (2020) Macrophage Migration Inhibitory Factor Is Regulated by HIF-1α and cAMP and Promotes Renal Cyst Cell Proliferation in a Macro-phage-Independent Manner. Journal of Molecular Medicine, 98, 1547-1559. [Google Scholar] [CrossRef] [PubMed]
[5] Chang, M.Y., et al. (2022) Effects of Suramin on Polycystic Kidney Disease in a Mouse Model of Polycystin-1 Deficiency. International Journal of Molecular Sciences, 23, Article 8499. [Google Scholar] [CrossRef] [PubMed]
[6] Agborbesong, E., et al. (2022) Molecular Mechanisms of Epige-netic Regulation, Inflammation, and Cell Death in ADPKD. Frontiers in Molecular Biosciences, 9, Article ID: 922428. [Google Scholar] [CrossRef] [PubMed]
[7] Grover, M.M. and Jenkins, T.G. (2020) Transgenerational Epige-netics: A Window into Paternal Health Influences on Offspring. Urologic Clinics of North America, 47, 219-225. [Google Scholar] [CrossRef] [PubMed]
[8] Younesian, S., et al. (2022) The DNA Methylation in Neurological Diseases. Cells, 11, Article 3439. [Google Scholar] [CrossRef] [PubMed]
[9] Kenter, A.T., et al. (2020) Cystic Renal-Epithelial Derived Induced Plu-ripotent Stem Cells from Polycystic Kidney Disease Patients. Stem Cells Translational Medicine, 9, 478-490. [Google Scholar] [CrossRef] [PubMed]
[10] Li, L.X., et al. (2022) Single-Cell and CellChat Resolution Identifies Collecting Duct Cell Subsets and Their Communications with Adjacent Cells in PKD Kidneys. Cells, 12, Article 45. [Google Scholar] [CrossRef] [PubMed]
[11] Zhou, X. and Torres, V.E. (2022) Emerging Therapies for Autosomal Dominant Polycystic Kidney Disease with a Focus on cAMP Signaling. Frontiers in Molecular Biosciences, 9, Article ID: 981963. [Google Scholar] [CrossRef] [PubMed]
[12] Jamadar, A., et al. (2021) The Tyrosine-Kinase Inhibitor Nintedanib Ameliorates Autosomal-Dominant Polycystic Kidney Disease. Cell Death & Disease, 12, Article No. 947. ttps://doi.org/10.1038/s41419-021-04248-9
[13] McConnachie, D.J., Stow, J.L. and Mallett, A.J. (2021) Ciliopathies and the Kidney: A Review. American Journal of Kidney Diseases, 77, 410-419. [Google Scholar] [CrossRef] [PubMed]
[14] Pellegrini, H., et al. (2023) Cleavage Fragments of the C-Terminal Tail of Polycystin-1 Are Regulated by Oxidative Stress and Induce Mitochondrial Dysfunction. Journal of Biological Chemistry, 299, Article ID: 105158. [Google Scholar] [CrossRef] [PubMed]
[15] Wang, Y., et al. (2023) The Diverse Effects of Pathogenic Point Mutations on Ion Channel Activity of a Gain-of-Function Polycystin-2. Journal of Biological Chemistry, 299, Article ID: 104674. [Google Scholar] [CrossRef] [PubMed]
[16] Toro, T.B., et al. (2023) Endogenous Expression of Inac-tive Lysine Deacetylases Reveals Deacetylation-Dependent Cellular Mechanisms. PLOS ONE, 18, e0291779. [Google Scholar] [CrossRef] [PubMed]
[17] Carmona, B., et al. (2023) Tubulin Post-Translational Modifica-tions: The Elusive Roles of Acetylation. Biology, 12, Article 561. [Google Scholar] [CrossRef] [PubMed]
[18] Li, X. (2020) Epigenetics and Cell Cycle Regulation in Cystogenesis. Cell Signal, 68, Article ID: 109509. [Google Scholar] [CrossRef] [PubMed]
[19] Dai, E., et al. (2021) Epigenetic Modulation of Antitumor Im-munity for Improved Cancer Immunotherapy. Molecular Cancer, 20, Article No. 171. [Google Scholar] [CrossRef] [PubMed]
[20] Li, L.X., et al. (2022) Cross Talk between Lysine Methyltrans-ferase Smyd2 and TGF-β-Smad3 Signaling Promotes Renal Fibrosis in Autosomal Dominant Polycystic Kidney Disease. American Journal of Physiology-Renal Physiology, 323, F227-F242. [Google Scholar] [CrossRef] [PubMed]
[21] Li, L.X., et al. (2020) Cross-Talk between CDK4/6 and SMYD2 Regulates Gene Transcription, Tubulin Methylation, and Ciliogenesis. Science Advances, 6, eabb3154. [Google Scholar] [CrossRef] [PubMed]
[22] Gao, X., Leone, G.W. and Wang, H. (2020) Cyclin D-CDK4/6 Func-tions in Cancer. Advances in Cancer Research, 148, 147-169. [Google Scholar] [CrossRef] [PubMed]
[23] Swenson-Fields, K.I., et al. (2013) Macrophages Promote Poly-cystic Kidney Disease Progression. Kidney International, 83, 855-864. [Google Scholar] [CrossRef] [PubMed]
[24] Zimmerman, K.A., Hopp, K. and Mrug, M. (2020) Role of Chemokines, Innate and Adaptive Immunity. Cellular Signalling, 73, Article ID: 109647. [Google Scholar] [CrossRef] [PubMed]
[25] Dwivedi, N., et al. (2023) Myofibroblast Depletion Reduces Kidney Cyst Growth and Fibrosis in Autosomal Dominant Polycystic Kidney Disease. Kidney International, 103, 144-155. [Google Scholar] [CrossRef] [PubMed]
[26] Fan, Y.N., et al. (2023) Progress in Nanoparticle-Based Regulation of Immune Cells. Medical Review, 3, 152-179. [Google Scholar] [CrossRef] [PubMed]
[27] Raphael, I., Joern, R.R. and Forsthuber, T.G. (2020) Memory CD4+ T Cells in Immunity and Autoimmune Diseases. Cells, 9, Article 531. [Google Scholar] [CrossRef] [PubMed]
[28] Zhang, J.Q.J., Saravanabavan, S. and Rangan, G.K. (2021) Effect of Reducing Ataxia-Telangiectasia Mutated (ATM) in Experimental Autosomal Dominant Polycystic Kidney Disease. Cells, 10, Article 532. [Google Scholar] [CrossRef] [PubMed]
[29] Zheng, Q., et al. (2022) Non-Coding RNAs as Potential Biomarkers and Therapeutic Targets in Polycystic Kidney Disease. Frontiers in Physiology, 13, Article ID: 1006427. [Google Scholar] [CrossRef] [PubMed]